Equillium Inc
NASDAQ:EQ
Equillium Inc
Cash & Cash Equivalents
Equillium Inc
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Equillium Inc
NASDAQ:EQ
|
Cash & Cash Equivalents
$15.4m
|
CAGR 3-Years
-42%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Cash & Cash Equivalents
$5.5B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-33%
|
CAGR 10-Years
-4%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash & Cash Equivalents
$10B
|
CAGR 3-Years
23%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
0%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash & Cash Equivalents
$12B
|
CAGR 3-Years
14%
|
CAGR 5-Years
15%
|
CAGR 10-Years
12%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash & Cash Equivalents
$6.1B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
14%
|
CAGR 10-Years
26%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash & Cash Equivalents
$17.9B
|
CAGR 3-Years
84%
|
CAGR 5-Years
62%
|
CAGR 10-Years
39%
|
|
Equillium Inc
Glance View
Equillium, Inc. engages in the development of products for severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company is headquartered in La Jolla, California and currently employs 45 full-time employees. The company went IPO on 2018-10-12. The firm develops products to treat severe autoimmune and inflammatory disorders with unmet medical needs. The firm's initial product candidate, itolizumab (EQ001), is a clinical-stage, monoclonal antibody that selectively targets CD6, a co-stimulatory receptor differentially expressed on subsets of pro-inflammatory T cells. The firm's CD6 plays a central role in the modulation of effector T cell, or Teff cell, activity and trafficking. Activated Teff cells drive several immuno-inflammatory diseases across therapeutic areas including transplant science, systemic autoimmunity, pulmonary, neurologic, gastrointestinal, renal, vascular, ophthalmic and dermatologic disorders. The company also provides structured-domain peptides, including BNZ-1 and BNZ-2, entirely in-house from product discovery platform. These lead product candidates are multi-specific inhibitors that targets range of immuno-inflammatory indication.
See Also
What is Equillium Inc's Cash & Cash Equivalents?
Cash & Cash Equivalents
15.4m
USD
Based on the financial report for Sep 30, 2024, Equillium Inc's Cash & Cash Equivalents amounts to 15.4m USD.
What is Equillium Inc's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
-11%
Over the last year, the Cash & Cash Equivalents growth was -55%. The average annual Cash & Cash Equivalents growth rates for Equillium Inc have been -42% over the past three years , -11% over the past five years .
You don't have any saved screeners yet